Discontinuation of Antithrombotic Treatment Following Patent Foramen Ovale Closure in Young Patients With Cryptogenic Stroke. The HALTI Trial
Status: Recruiting
Location: See location...
Intervention Type: Other
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY
To determine the safety of antithrombotic treatment discontinuation 12 months following successful transcatheter PFO closure.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 60
Healthy Volunteers: t
View:
• Successful transcatheter PFO closure with any approved device
• Patients ≤60 years diagnosed with a cryptogenic stroke/TIA who have undergone successful transcatheter PFO closure
Locations
Other Locations
Canada
IUCPQ
RECRUITING
Québec
Contact Information
Primary
Josep Rodes-Cabau, MD
josep.rodes@criucpq.ulaval.ca
4186568711
Backup
Melanie Cote, MSc
melanie.cote@criucpq.ulaval.ca
14186537270
Time Frame
Start Date: 2020-07-08
Estimated Completion Date: 2032-08-01
Participants
Target number of participants: 100
Treatments
Experimental: Antiplatelet treatment discontinuation
At 12 months post-PFO closure, patients will discontinue the antiplatelet treatment. All patients will undergo a clinical evaluation and cerebral MRI at 12 months (before antiplatelet treatment cessation) and at 24 months post-PFO closure.
Related Therapeutic Areas
Sponsors
Leads: Josep Rodes-Cabau